SBC Medical Group Holdings Incorporated logo

SBC Medical Group Holdings Incorporated

SBCWW

NASDAQIndustrialsSpecialty Business Services

Previous close

$0.335

+$0.0256 · +8.27%

Aug 21, 2:44 PM ET

SBCWW company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

66

Undervalued

Momentum

56

Neutral

Sentiment

67

Bullish

Risk resilience

54

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SBC Medical Group Holdings Incorporated (SBCWW) specializes in providing comprehensive management and support services to a network of aesthetic treatment centers. The company operates globally, with a significant presence in Japan, Vietnam, and the United States, alongside its other international activities. SBC's service portfolio for its franchisee clinics is extensive, covering everything from strategic advertising and marketing campaigns to human resources management, including staff recruitment and professional training programs. They also manage booking reservations for clients, assist with employee housing and facility rentals, and oversee the entire process of clinic construction and design. Furthermore, SBC facilitates the procurement of essential medical equipment and consumable supplies. In addition to these foundational services, SBC Medical Group offers advanced IT software solutions and a diverse range of cosmetic and reconstructive medical procedures. These treatments encompass common aesthetic enhancements such as breast augmentation, liposuction, and various rejuvenation therapies designed to address wrinkles, acne, scars, cellulite, excess fat, skin discoloration, and other visible signs of aging. Specialized services include laser skin toning and spot removal, double eyelid surgery, rhinoplasty (nose reshaping), and treatments for osmidrosis and hyperhidrosis. The company also provides hair transplants, gynecological formation treatments, laser hair removal, facial contouring surgeries, cosmetic dental procedures, and tattoo removal. Ophthalmic interventions like LASIK eye surgery and lateral canthoplasty are offered, alongside brow lifts, androgenetic alopecia (male pattern baldness) treatment, and methods for preventing cheek sagging. Established in 2000, the company maintains its corporate headquarters in Irvine, California.

Industry
Specialty Business Services
Sector
Industrials
Headquarters
US
CEO
Yoshiyuki Aikawa
Listed since
Aug 9, 2022
Employees
863

Market position

Day range

Current $0.335

52-week range

Current $0.335

Open
$0.1749
Previous close
$0.3094
Volume
2.33K
0.06× average
Average volume
42.02K
Average daily volume
Market cap
34.45M USD
Beta
0.59
Market reference 1
50-day average
$0.2316
+44.68% above average
200-day average
$0.227
+47.60% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-91.23M USD
P/E (TTM)
0.71×
P/B (TTM)
0.13×
P/S (TTM)
0.2×
EV / EBITDA
-1.07×
Earnings yield
243.85%
Free cash flow yield
174.81%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
71.85%
Operating margin
37.34%
Net margin
27.99%
Return on equity
20.54%
Return on assets
13.40%
Return on invested capital
12.61%

Financial health

Debt / equity
0.18×
Current ratio
3.78×
Altman Z-score
2.64
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%54%25%-4%Gross margin, FY2022: 65.94%Gross margin, FY2023: 70.94%Gross margin, FY2024: 75.97%Gross margin, FY2025: 73.32%Operating margin, FY2022: 11.55%Operating margin, FY2023: 36.51%Operating margin, FY2024: 34.23%Operating margin, FY2025: 38.87%Net margin, FY2022: 3.63%Net margin, FY2023: 20.34%Net margin, FY2024: 22.69%Net margin, FY2025: 29.37%FY2022FY2023FY2024FY2025
Gross margin FY2022 65.94%. Gross margin FY2023 70.94%. Gross margin FY2024 75.97%. Gross margin FY2025 73.32%. Operating margin FY2022 11.55%. Operating margin FY2023 36.51%. Operating margin FY2024 34.23%. Operating margin FY2025 38.87%. Net margin FY2022 3.63%. Net margin FY2023 20.34%. Net margin FY2024 22.69%. Net margin FY2025 29.37%.

Income trends

Revenue

173.61M USD-15.48%

Operating income

67.49M USD-4.01%

Net income

50.99M USD+9.38%
Income trends across reported periods225.33M USD145.69M USD66.05M USD−13.6M USDRevenue, FY2022: 174.16M USDRevenue, FY2023: 193.54M USDRevenue, FY2024: 205.42M USDRevenue, FY2025: 173.61M USDOperating income, FY2022: 20.12M USDOperating income, FY2023: 70.66M USDOperating income, FY2024: 70.3M USDOperating income, FY2025: 67.49M USDNet income, FY2022: 6.32M USDNet income, FY2023: 39.37M USDNet income, FY2024: 46.61M USDNet income, FY2025: 50.99M USDFY2022FY2023FY2024FY2025
Revenue FY2022 174.16M USD. Revenue FY2023 193.54M USD. Revenue FY2024 205.42M USD. Revenue FY2025 173.61M USD. Operating income FY2022 20.12M USD. Operating income FY2023 70.66M USD. Operating income FY2024 70.3M USD. Operating income FY2025 67.49M USD. Net income FY2022 6.32M USD. Net income FY2023 39.37M USD. Net income FY2024 46.61M USD. Net income FY2025 50.99M USD.
Metric (USD)FY2025FY2024FY2023FY2022
Revenue173.61M USD205.42M USD193.54M USD174.16M USD
Cost of goods sold46.32M USD49.37M USD56.24M USD59.33M USD
Gross profit127.28M USD156.05M USD137.3M USD114.83M USD
Selling, general, and administrative59.8M USD70.69M USD66.24M USD93.48M USD
Operating expenses59.8M USD85.75M USD66.64M USD94.72M USD
Interest income198.32K USD19.94K USD86.75K USD472.38K USD
Interest expense160.58K USD28.3K USD45.29K USD31.44K USD
Depreciation and amortization2.68M USD3.8M USD12.25M USD5.93M USD
Operating income67.49M USD70.3M USD70.66M USD20.12M USD
Net income50.99M USD46.61M USD39.37M USD6.32M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
44%
4 beats, 5 misses, 0 met estimates
Average EPS surprise
-30.62%
9 comparable reports
Latest EPS result
0.1
Estimate 0.12 · Miss by 13.87%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.250.170.090.02Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual 0.06, estimate 0.17, surprise -64.71%, Miss. Q2 2025, reported May 15, 2025: actual 0.21, estimate 0.15, surprise +40.00%, Beat. Q3 2025, reported Aug 13, 2025: actual 0.02, estimate 0.135, surprise -85.19%, Miss. Q4 2025, reported Nov 14, 2025: actual 0.12, estimate 0.11, surprise +9.09%, Beat. Q1 2026, reported Mar 27, 2026: actual 0.14, estimate 0.12, surprise +17.15%, Beat. Q2 2026, reported May 14, 2026: actual 0.11, estimate 0.098, surprise +12.22%, Beat. Q3 2026, reported Aug 13, 2026: actual 0.1, estimate 0.116, surprise -13.87%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 0.118, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates59.85M52.32M44.79M37.26MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual 44M USD, estimate 56.85M USD, surprise -22.60%, Miss. Q2 2025, reported May 15, 2025: actual 47.33M USD, estimate 57.55M USD, surprise -17.76%, Miss. Q3 2025, reported Aug 13, 2025: actual 43.36M USD, estimate 44.71M USD, surprise -3.03%, Miss. Q4 2025, reported Nov 14, 2025: actual 43.35M USD, estimate 45.18M USD, surprise -4.03%, Miss. Q1 2026, reported Mar 27, 2026: actual 39.57M USD, estimate 45.44M USD, surprise -12.92%, Miss. Q2 2026, reported May 14, 2026: actual 43.06M USD, estimate 41.66M USD, surprise +3.37%, Beat. Q3 2026, reported Aug 13, 2026: actual 49.19M USD, estimate 45.37M USD, surprise +8.41%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 47.91M USD, surprise —, Comparison unavailable.

SBCWW peers

Continue in GoAI

Research SBCWW

research.disclaimer